<DOC>
	<DOCNO>NCT02634541</DOCNO>
	<brief_summary>Axial spondyloarthritis inflammatory rheumatic disease mainly affect joint spine sacroiliac joint . Inflammatory pathways likely central link axial spondyloarthritis know increase risk atherosclerotic morbidity . Positron emission tomography ( PET ) sensitive method detect inflammatory focus clinical practice . A small study demonstrate PET image together compute tomography ( PET/CT ) detect inflamed tissue relevant patient group . One study suggest antirheumatic treatment diminishes inflammation detect PET/CT . No study far disclose whether aortic inflammation present patient spondyloarthritis , whether inflammation would wane efficient antirheumatic treatment . The current study aim grade articular aortic inflammatory signal PET/CT image antirheumatic treatment clinically active axial spondyloarthritis . Sixty patient age 18-75 year axial spondyloarthritis radiologic sacroiliitis detect either MRI X-ray recruit . Twenty DMARD-naive , 40 patient axial spondyloarthritis resistant sulfasalazine conventional antirheumatic drug . In addition , approximately 30 patient without spondyloarthritis stable coronary heart disease approximately 20 healthy control take historical control . All axial spondyloarthritis patient PET/CT scan inclusion study . The DMARD-naive patient ( n=20 ) start sulfasalazine-based regimen 12 week , time point second PET scan subgroup . Adalimumab commence without remission 12 week . After another 16 week , adalimumab scan PET/CT third time . The subgroup active disease spite prior conventional treatment ( n=40 ) also scan PET/CT right enrolment 16-week treatment adalimumab . The first 15 patient form pilot group , use check validity power calculation . The project give essential new information PET-detectable inflammation patient axial spondyloarthritis . The result publish international publication series . The publication form basis doctoral thesis . Funding project come Abbvie Ltd .</brief_summary>
	<brief_title>Adalimumab Alleviating Inflammation Patients With Axial Spondyloarthritis</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Sulfasalazine</mesh_term>
	<criteria>Axial spondyloarthritis ( ASAS criterion ) radiologic sacroiliitis detect either MRI Xray . Psoriasis psoriasis arthropathy Inflammatory bowel disease Unwillingness participate study additional imaging protocol Expected lifespan less &lt; 1 year Diabetes ( improve PET image quality ) Probable noncompliance Pregnancy Age &lt; 18 year &gt; 75 year Contraindication adalimumab Methotrexate use within previous 6 month A biologic medicine use within previous 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>